Efficacy and safety of antiangiogenic agents or chemotherapy plus EGFR-TKIs in advanced non-small cell lung cancer: A systematic review and network meta-analysis.
Jiali DaiXinyin LiuJun LiTianyu QuYanan CuiShidai JinErbao ZhangRen-Hua GuoPublished in: Thoracic cancer (2023)
Based on the efficacy and safety, the combination of chemotherapy with EGFR-TKIs is considered the best combination treatment options in advanced NSCLC with EGFR mutation.